NASDAQ:CABA Cabaletta Bio (CABA) Stock Price, News & Analysis → Trump’s Gift Could Unleash $51 Billion in New Wealth (From Wealthpin Pro) (Ad) Free CABA Stock Alerts $10.19 +0.26 (+2.62%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$9.78▼$10.2750-Day Range$9.93▼$18.8252-Week Range$9.02▼$26.35Volume1.26 million shsAverage Volume783,883 shsMarket Capitalization$491.97 millionP/E RatioN/ADividend YieldN/APrice Target$34.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Cabaletta Bio alerts: Email Address Cabaletta Bio MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside236.9% Upside$34.33 Price TargetShort InterestHealthy18.85% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.02Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.07) to ($2.39) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.56 out of 5 starsMedical Sector727th out of 924 stocksBiological Products, Except Diagnostic Industry125th out of 151 stocks 3.5 Analyst's Opinion Consensus RatingCabaletta Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCabaletta Bio has only been the subject of 4 research reports in the past 90 days.Read more about Cabaletta Bio's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted18.85% of the outstanding shares of Cabaletta Bio have been sold short.Short Interest Ratio / Days to CoverCabaletta Bio has a short interest ratio ("days to cover") of 8.1.Change versus previous monthShort interest in Cabaletta Bio has recently decreased by 11.22%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCabaletta Bio does not currently pay a dividend.Dividend GrowthCabaletta Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CABA. Previous Next 3.3 News and Social Media Coverage News SentimentCabaletta Bio has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Cabaletta Bio this week, compared to 3 articles on an average week.Search InterestOnly 11 people have searched for CABA on MarketBeat in the last 30 days. This is a decrease of -73% compared to the previous 30 days.MarketBeat Follows3 people have added Cabaletta Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cabaletta Bio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.88% of the stock of Cabaletta Bio is held by insiders.Read more about Cabaletta Bio's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Cabaletta Bio are expected to decrease in the coming year, from ($2.07) to ($2.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cabaletta Bio is -5.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cabaletta Bio is -5.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCabaletta Bio has a P/B Ratio of 2.22. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Cabaletta Bio's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Cabaletta Bio Stock (NASDAQ:CABA)Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.Read More CABA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CABA Stock News HeadlinesMay 29, 2024 | finance.yahoo.comCabaletta Bio to Participate in the Jefferies Global Healthcare ConferenceMay 25, 2024 | americanbankingnews.comCabaletta Bio (NASDAQ:CABA) Receives "Buy" Rating from HC WainwrightMay 16, 2024 | msn.comCabaletta Bio Reports Promising Advances in Autoimmune Disease Trials, Looks to Future InnovationsMay 15, 2024 | markets.businessinsider.comWilliam Blair Reaffirms Their Buy Rating on Cabaletta Bio (CABA)May 15, 2024 | investorplace.comCABA Stock Earnings: Cabaletta Bio Misses EPS for Q1 2024May 15, 2024 | finance.yahoo.comCabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 15, 2024 | globenewswire.comCabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 15, 2024 | msn.comCabaletta Bio to Present at H.C. Wainwright BioConnect Investor ConferenceMay 13, 2024 | globenewswire.comCabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQMay 10, 2024 | msn.comRetinopathy With Long-Term HCQ Use: Large Study IDs Risk FactorsMay 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cabaletta Bio as CABA-201 Enters RESET Trial with Promising Therapeutic PotentialApril 27, 2024 | investing.comCabaletta Bio Inc (CABA)April 18, 2024 | msn.comPhilly-area biotech is worried about Congress’ crackdown on Chinese manufacturersApril 17, 2024 | msn.com🛠️ One Philly rowhouse at a time | Morning NewsletterMarch 23, 2024 | investing.comStifel lifts Cabaletta Bio target to $32 on myositis positionMarch 23, 2024 | finance.yahoo.comCabaletta Bio Inc (CABA) Earnings: Aligns with EPS Projections, Forecasts Extended Cash RunwayMarch 22, 2024 | markets.businessinsider.comStrong Buy on Cabaletta Bio: Promising CAR T Candidate and Robust Financial OutlookMarch 21, 2024 | markets.businessinsider.comCabaletta Bio Earns ‘Buy’ Rating on Impressive Clinical Progress and Strategic Market PositioningMarch 21, 2024 | investorplace.comCABA Stock Earnings: Cabaletta Bio Misses EPS for Q4 2023March 21, 2024 | msn.comCabaletta gets FDA orphan drug status for systemic sclerosis drugMarch 21, 2024 | finance.yahoo.comCabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 21, 2024 | globenewswire.comCabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 20, 2024 | markets.businessinsider.comCabaletta Bio Says FDA Grants Orphan Drug Designation To CABA-201 To Treat Systemic SclerosisMarch 20, 2024 | finance.yahoo.comCabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic SclerosisMarch 19, 2024 | msn.comA major cog in Philly biotech is in congressional crosshairs for its Chinese ownershipSee More Headlines Receive CABA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cabaletta Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/21/2024Today6/02/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:CABA CUSIPN/A CIK1759138 Webwww.cabalettabio.com Phone267-759-3100FaxN/AEmployees118Year FoundedN/APrice Target and Rating Average Stock Price Target$34.33 High Stock Price Target$50.00 Low Stock Price Target$25.00 Potential Upside/Downside+236.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($1.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-67,680,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-38.77% Return on Assets-36.09% Debt Debt-to-Equity RatioN/A Current Ratio12.66 Quick Ratio12.66 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.59 per share Price / Book2.22Miscellaneous Outstanding Shares48,280,000Free Float43,507,000Market Cap$491.97 million OptionableOptionable Beta2.52 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Steven A. Nichtberger M.D. (Age 63)Co-Founder, Chairman, CEO & President Comp: $1.02MDr. Gwendolyn K. Binder Ph.D. (Age 49)President of Science & Technology Comp: $722.62kDr. David J. Chang FACR (Age 61)M.D., M.P.H., Chief Medical Officer Comp: $721.85kDr. Michael C. Milone M.D.Ph.D., Co-Founder & Co-Chair of Scientific Advisory BoardDr. Aimee Payne M.D.Ph.D., Co-Founder & Co-Chair of Scientific Advisory BoardMr. Anup Marda M.B.A. (Age 46)Chief Financial Officer Comp: $548.2kDr. Samik Basu M.D.Chief Scientific OfficerMr. Michael Gerard J.D. (Age 44)General Counsel & Secretary Ms. Heather Harte-Hall M.Sc.Chief Compliance OfficerMs. Martha O'ConnorChief Human Resources OfficerMore ExecutivesKey CompetitorsOPKO HealthNASDAQ:OPKKymera TherapeuticsNASDAQ:KYMRBeam TherapeuticsNASDAQ:BEAMFusion PharmaceuticalsNASDAQ:FUSNInhibrxNASDAQ:INBXView All CompetitorsInsiders & InstitutionsLynx1 Capital Management LPSold 27,428 shares on 5/30/2024Ownership: 4.314%Teachers Retirement System of The State of KentuckyBought 17,905 shares on 5/28/2024Ownership: 0.037%Blackstone Inc.Sold 300,714 shares on 5/16/2024Ownership: 0.100%California State Teachers Retirement SystemBought 1,711 shares on 5/16/2024Ownership: 0.065%Bayesian Capital Management LPBought 11,187 shares on 5/16/2024Ownership: 0.024%View All Insider TransactionsView All Institutional Transactions CABA Stock Analysis - Frequently Asked Questions Should I buy or sell Cabaletta Bio stock right now? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cabaletta Bio in the last twelve months. There are currently 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CABA shares. View CABA analyst ratings or view top-rated stocks. What is Cabaletta Bio's stock price target for 2024? 9 equities research analysts have issued twelve-month price targets for Cabaletta Bio's stock. Their CABA share price targets range from $25.00 to $50.00. On average, they predict the company's stock price to reach $34.33 in the next twelve months. This suggests a possible upside of 236.9% from the stock's current price. View analysts price targets for CABA or view top-rated stocks among Wall Street analysts. How have CABA shares performed in 2024? Cabaletta Bio's stock was trading at $22.70 at the beginning of the year. Since then, CABA stock has decreased by 55.1% and is now trading at $10.19. View the best growth stocks for 2024 here. Are investors shorting Cabaletta Bio? Cabaletta Bio saw a drop in short interest in May. As of May 15th, there was short interest totaling 9,100,000 shares, a drop of 11.2% from the April 30th total of 10,250,000 shares. Based on an average daily volume of 1,130,000 shares, the days-to-cover ratio is presently 8.1 days. View Cabaletta Bio's Short Interest. When is Cabaletta Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our CABA earnings forecast. How were Cabaletta Bio's earnings last quarter? Cabaletta Bio, Inc. (NASDAQ:CABA) issued its quarterly earnings results on Thursday, March, 21st. The company reported ($0.46) earnings per share for the quarter, missing analysts' consensus estimates of ($0.39) by $0.07. What ETFs hold Cabaletta Bio's stock? ETFs with the largest weight of Cabaletta Bio (NASDAQ:CABA) stock in their portfolio include Alger Mid Cap 40 ETF (FRTY).Alger 35 ETF (ATFV). What other stocks do shareholders of Cabaletta Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cabaletta Bio investors own include Alector (ALEC), Editas Medicine (EDIT), Kaleido Biosciences (KLDO), Sorrento Therapeutics (SRNE), Homology Medicines (FIXX), Skyworks Solutions (SWKS), CrowdStrike (CRWD), Precision BioSciences (DTIL), Invitae (NVTA) and Pfizer (PFE). When did Cabaletta Bio IPO? Cabaletta Bio (CABA) raised $87 million in an initial public offering (IPO) on Friday, October 25th 2019. The company issued 5,800,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Cowen and Company and Evercore Group acted as the underwriters for the IPO. Who are Cabaletta Bio's major shareholders? Cabaletta Bio's stock is owned by a number of institutional and retail investors. Top institutional investors include Jennison Associates LLC (7.31%), Vanguard Group Inc. (4.86%), Lynx1 Capital Management LP (4.31%), Bain Capital Life Sciences Investors LLC (3.46%), Price T Rowe Associates Inc. MD (1.31%) and StemPoint Capital LP (0.00%). Insiders that own company stock include Anup Marda, Catherine Bollard, Gwendolyn Binder, Steven Nichtberger and Ventures V LP 5Am. View institutional ownership trends. How do I buy shares of Cabaletta Bio? Shares of CABA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CABA) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersBiden Nomination CANCELED?The Freeport SocietyTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap Profits[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaBiden replacement revealed?Paradigm PressThis unknown company solves the biggest issue with AIManward Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cabaletta Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.